ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: New Caution Urged Over Sole Oral MS Drug On the Market

(This story has been posted on The Wall Street Journal Online's Health Blog at The FDA says the only oral multiple-sclerosis drug on the market -- Novartis's Gilenya -- shouldn't be used in patients with a recent history of stroke or some heart problems. As WSJ reports, a safety review of the treatment was prompted by a report in November of a 59-year-old patient dying in the U.S. less than a day after taking the first dose of the drug. Although the agency said an exact cause of the patient's death couldn't be identified, it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the treatment can lower a person's heart rate temporarily. Patients who have had a stroke or heart trouble within the past six months shouldn't take the drug, the FDA says. It also shouldn't be used in patients taking some kinds of medicines to treat heart arrhythmias. The FDA warning comes after Europe's drug regulator last month requested stronger safety warnings. The U.S. agency is currently reviewing another oral MS drug from Biogen Idec designed to work through a different mechanism than Gilenya. -For continuously updated news from The Wall Street Journal, see at

Stock News for Novartis (NVS)
11/25/201511:30:00Prescription Skin Drugs Explode in Costs, Study Shows
11/23/201509:20:02The FDA Approves Exelixis, Inc's New Cancer Drug
11/23/201508:46:033 Dividend Stocks You Don't Have to Babysit
11/20/201517:35:00Novartis Finalizes Settlement With Justice Department
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/19/201509:16:045 Things GlaxoSmithKline PLC Wants You to Know
11/17/201511:40:56Why Ophthotech Corporation's Shares Soared in October
11/07/201513:40:09Momenta Slowed (Temporarily)
11/06/201512:16:03Why XOMA Shares Are Crashing
11/04/201510:20:02Is This Drug Going to Be a Big Threat to Biogen and Novartis...
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/31/201509:21:03Generic Copaxone Isn't Derailing Teva Pharmaceuticals...Yet
10/29/201516:07:02GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery
10/28/201509:20:00GlaxoSmithKline Sees Higher Sales
10/28/201509:03:00GlaxoSmithKline Sees Higher Sales in Third Quarter But Lower...
10/27/201511:15:00Novartis Profit Hurt by U.S. Settlement -- 4th Update
10/27/201507:49:00Novartis Profit Hurt by U.S. Settlement-- Third Update
10/27/201505:50:00Global Stocks Fall Ahead of Fed Meeting
10/27/201505:05:00Novartis Profit Hurt by U.S. Settlement -- 2nd Update
10/27/201504:57:00Novartis Profit Hurt by U.S. Settlement -- Update

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations